T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease.
Do all patients need it first line?
Probably not. But great option for higher risk.
#bcsm #oncosky
Do all patients need it first line?
Probably not. But great option for higher risk.
#bcsm #oncosky
Reposted from
Elisabetta Bonzano MD, PhD
📌 Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com/media-centre...
@oncoalert.bsky.social
www.astrazeneca.com/media-centre...
@oncoalert.bsky.social
Comments